ReviewFrontiers in cell and developmental biology2026
Precision immuno-oncology in oral cancer: latest trends in biomarkers, novel drug development and nanoparticle-based therapeutic platforms.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma poses a significant global health burden, with over 370,000 annual cases and poor 5-year survival rates of 50%-60%, driven by risk factors like tobacco and alcohol. Despite advances in surgery, radiotherapy, and chemotherapy, functional morbidity and resistance necessitate precision immuno-oncology approaches. This review explores the tumour immune microenvironment in oral squamous cell carcinoma, characterized by immunosuppressive elements like M2 macrophages, myeloid-derived suppressor cells, and regulatory T cells, alongside spatial heterogeneity that complicates therapy. Biomarkers for patient selection include programmed death-ligand1 expression (via combined positive scoring), tumour mutational burden, neoantigen load, interferon-gamma-γ signatures, cytolytic scores, peripheral circulating tumour DNA, and single-cell/spatial profiling, though standardization remains critical. Immunotherapy has transformed oral squamous cell carcinoma management, with programmed cell death protein-1 inhibitors like nivolumab and pembrolizumab showing survival benefits in trials, particularly in programmed cell death protein-L1-positive cases. Emerging strategies encompass next-generation checkpoints (Lymphocyte activation gene-3, T-cell immunoreceptor with Ig and ITIM domains, OX40), personalized neoantigen vaccines, adoptive cell therapies (Tumour-Infiltrating Lymphocytes, Chimeric Antigen Receptor T-cell therapy), and rational combinations to counter resistance. Nanomedicine platforms-liposomes, polymeric nanoparticles, gold-based systems-enhance drug delivery, reprogram the Tumour and immune microenvironment, and enable chemo-immuno-photothermal synergies, addressing mucosal barriers and toxicity. Future priorities include biomarker validation via prospective registries, scalable Good Manufacturing Practice nanoplatforms, AI-driven multi-omic modeling, and federated learning for predictive analytics. By integrating tumour genomics, immune profiling, and advanced delivery, precision immuno-oncology holds promise to improve response rates, durability, and quality of life in oral squamous cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.